Merrimack Pharmaceuticals, Inc. (MACK) Financial Statements (2023 and Earlier)

Company Profile

Business Address ONE BROADWAY
CAMBRIDGE, MA 02142
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:14,20014,00016,60071,30093,44121,524185,606
Cash and cash equivalents14,20314,03816,58020,07993,44121,524185,606
Short-term investments   51,199   
Other undisclosed cash, cash equivalents, and short-term investments(3)(38)2022   
Restricted cash and investments   584102102101
Receivables    10017,4696,483
Inventory, net of allowances, customer advances and progress billings     14,5543,717
Inventory     14,5543,717
Other undisclosed current assets4832,5442,0924,2181,4033,7865,487
Total current assets:14,68316,54418,69276,10295,04657,435201,394
Noncurrent Assets
Property, plant and equipment   2,2696,46715,76521,915
Long-term investments and receivables   7,42810,551  
Long-term investments   7,42810,551  
Intangible assets, net (including goodwill)     7,58210,960
Goodwill     3,6053,605
Intangible assets, net (excluding goodwill)     3,9777,355
Restricted cash and investments    674674584
Other noncurrent assets662321,3902,7444,5882727
Total noncurrent assets:662321,39012,44122,28024,04833,486
TOTAL ASSETS:14,74916,77620,08288,543117,32681,483234,880
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:5627702,71413,67717,60649,98252,082
Accounts payable1201232711,0342,8873,3845,049
Accrued liabilities1671943722,0825,66315,76014,295
Employee-related liabilities   2,3152,8849,1509,009
Taxes payable   83   
Interest and dividends payable    192,1193,060
Other undisclosed accounts payable and accrued liabilities2754532,0718,1636,15319,56920,669
Deferred rent credit   1,118
Deferred revenue and credits2,17138,24051,664
Other liabilities  56    
Total current liabilities:5627702,77014,79519,77788,222103,746
Noncurrent Liabilities
Long-term debt and lease obligation   14,873 216,861257,655
Long-term debt, excluding current maturities   14,873 216,861257,655
Liabilities, other than long-term debt   561,26529,05956,123
Deferred revenue and credits1,20929,05956,123
Other liabilities   5656  
Other undisclosed noncurrent liabilities      1,045
Total noncurrent liabilities:   14,9291,265245,920314,823
Total liabilities:5627702,77029,72421,042334,142418,569
Stockholders' equity
Stockholders' equity attributable to parent14,18716,00617,31258,81996,284(251,120)(183,928)
Common stock1,3341,3341,3341,3341,3341,3021,159
Additional paid in capital558,945558,309556,587580,771577,721702,377617,145
Accumulated other comprehensive loss   (9)   
Accumulated deficit(546,092)(543,637)(540,609)(523,277)(482,771)(954,799)(802,232)
Stockholders' equity attributable to noncontrolling interest     (1,539)239
Total stockholders' equity:14,18716,00617,31258,81996,284(252,659)(183,689)
TOTAL LIABILITIES AND EQUITY:14,74916,77620,08288,543117,32681,483234,880

Income Statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues  4,910 1,703144,27389,258
Revenue, net 144,27389,258
Gain on disposition of assets for financial service operations  4,910 
Financial services revenue1,703  
Cost of revenue     (6,912)(46)
Gross profit:  4,910 1,703137,36189,212
Operating expenses(2,472)(2,873)(22,359)(65,575)(105,287)(247,502)(218,783)
Other undisclosed operating income (loss)  (4,910) 7,818  
Operating loss:(2,472)(2,873)(22,359)(65,575)(95,766)(110,141)(129,571)
Nonoperating income (expense)20(141)(381)(2,887)10,3102681,016
Investment income, nonoperating20507771,29911,74327699
Other nonoperating income (expense) (191)370(3,230)(1,433)(8)917
Interest and debt expense  (971)(956)(34,650)(43,645)(19,232)
Loss from continuing operations before equity method investments, income taxes:(2,452)(3,014)(23,711)(69,418)(120,106)(153,518)(147,787)
Other undisclosed income from continuing operations before income taxes  9719561,703  
Loss from continuing operations before income taxes:(2,452)(3,014)(22,740)(68,462)(118,403)(153,518)(147,787)
Income tax expense (benefit)(3)(14)1,4737,69542,399  
Loss from continuing operations:(2,455)(3,028)(21,267)(60,767)(76,004)(153,518)(147,787)
Income from discontinued operations  3,93520,261546,872  
Net income (loss):(2,455)(3,028)(17,332)(40,506)470,868(153,518)(147,787)
Net income (loss) attributable to noncontrolling interest    1,1601,778(170)
Net income (loss) available to common stockholders, diluted:(2,455)(3,028)(17,332)(40,506)472,028(151,740)(147,957)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net income (loss):(2,455)(3,028)(17,332)(40,506)470,868(153,518)(147,787)
Comprehensive income (loss):(2,455)(3,028)(17,332)(40,506)470,868(153,518)(147,787)
Comprehensive income (loss), net of tax, attributable to noncontrolling interest    1,1601,778(170)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent  9(9)  74
Comprehensive income (loss), net of tax, attributable to parent:(2,455)(3,028)(17,323)(40,515)472,028(151,740)(147,883)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: